White Plains, NYNCT07091279Now EnrollingIRB Ready

Autism Spectrum Disorder Clinical Trial in White Plains, NY

Access cutting-edge autism spectrum disorder treatment through this phase 2 clinical trial at a research site in White Plains. Study-provided care at no cost to qualified participants.

Sponsored by Jeremy Veenstra-vanderweele

Quick Self-Assessment

See if you qualify for this White Plains location

Preparing your pre-screening questions…

Expert Care in White Plains

Access autism spectrum disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related autism spectrum disorder treatment provided free

Apply for This White Plains Location

Check if you qualify for this autism spectrum disorder clinical trial in White Plains, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to White Plains

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit White Plains site if eligible
  4. 4Begin participation

About This Autism Spectrum Disorder Study in White Plains

The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.

Sponsor: Jeremy Veenstra-vanderweele

Who Can Participate

Inclusion Criteria

Age between 12-40 years.
Clinical best-estimate diagnosis of autism spectrum disorder
Occurrence of severe challenging behaviors, such as aggression, self-injury, and/or severely disruptive or destructive behavior, leading to safety concerns or serious impact of the quality of life, at least weekly over the past 2 months before screening.
Score in the ASD range on the Autism Diagnostic Observation Schedule conducted at the time of study entry or in the past 5 years
Clinical Global Impression Severity scale (CGI-S) score of 4 or above at Baseline
Aberrant Behavior Checklist-2 Irritability/Agitation Subscale Score of 18 or above at Screening.
A resting pulse of greater than 60 and a resting blood pressure of greater than 100/60.
Participant must have a designated study partner who spends a minimum of 5 hours/week with the participant, and can, in the opinion of the investigator, provide a reliable report on the participant's behaviors, symptoms, and complete or supervise at-home safety monitoring and other assessments required during the study
Participants of childbearing potential who are sexually active must agree to practice effective contraception from time of screening through 30 days after their last dose of study drug. Effective contraception is the use of two methods of contraception: hormonal contraceptives or intrauterine device and barrier (i.e., condoms, diaphragm, or cervical cap).
Participant must be able to fully swallow study medication capsule.
English must be primary language for participant. Study partner must be able to consent in English and complete study related form in English.

Exclusion Criteria

Those who are unable to provide informed consent and have no parent/guardian/legally authorized representative to provide informed consent for study enrollment
Change in psychotropic medication or behavioral intervention (except when caused by vocational, habilitation, or school schedule) within two months before randomization.
Asthma or history of any disorder involving bronchoconstriction in the past 5 years.
Cardiovascular history in which the use of propranolol at high doses would be contraindicated, as determined by consulting cardiologist (such as AV block, sick sinus syndrome, valvular pathologies, cardiomyopathies, or vascular disease).
Uncontrolled seizure disorder (a seizure within the past year and/or changes in seizure medication in the previous six months).
Diabetes mellitus
History of lactose intolerance that requires the potential participant to abstain from all dairy products or to take lactase supplements.
Medical history of renal or hepatic impairment.
Medical history of hypoglycemia
Inability to provide blood testing when there is a medical indication for blood testing to allow clinical safety determination by the study safety physician
Depressive episode currently or within the previous six months
History of allergy or adverse reaction to propranolol or another beta-blocker
Current use of any of the following: propafenone, quinidine, amiodarone, lidocaine, digitalis glycosides, calcium channel blockers, ACE inhibitors, clonidine, alpha blockers, reserpine, inotropic agents (epinephrine), isoproterenol and dobutamine, nonsteroidal anti-inflammatory drugs (indomethacin), antidepressants (MAO inhibitors, tricyclics), anesthetic agents (methoxyflurane, trichloroethylene), warfarin, neuroleptics (haloperidol), thyroxine, alcohol
Any other medical disorder or medication which would contraindicate the use of propranolol.
Is judged to be inappropriate for the study for any reason by the Investigator
Has recently participated in another investigational medication study or device study within last 3 months
Participant is unable to complete blood pressure or ECG safety assessments
If female, is pregnant or breastfeeding.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in White Plains?

Yes, this clinical trial (NCT07091279) has an active research site in White Plains, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Autism Spectrum Disorder Treatment Options in White Plains, NY

If you're searching for autism spectrum disorder treatment options in White Plains, NY, this clinical trial (NCT07091279) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our White Plains research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced autism spectrum disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all autism spectrum disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in White Plains, NY

See all pulmonary embolism clinical trials recruiting in White Plains — not just this study.

Browse Pulmonary Embolism Trials in White Plains →

Browse More Trials by Condition

Pulmonary Embolism TrialsAutism TrialsUTI TrialsAll Conditions →

Ready to Join in White Plains?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · White Plains, NY